MARKET

SVA

SVA

Sinovac Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.47
0.00
0.00%
Suspension 16:00 04/24 EDT
OPEN
--
PREV CLOSE
6.47
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
6.25
MARKET CAP
639.90M
P/E (TTM)
88.15
1D
5D
1M
3M
1Y
5Y
Chile Has Deals for Third Doses of Sinovac and Pfizer If Needed
Chile secured deals for third doses of Covid-19 vaccines from Sinovac and Pfizer in the event they are needed in upcoming months, according to a government official.
Bloomberg · 2h ago
Guinea receives purchase of 300,000 Sinovac COVID-19 vaccines
reuters.com · 1d ago
Cambodia receives another batch of China's Sinovac COVID-19 vaccine
PHNOM PENH, April 17, 2021 (Xinhua via COMTEX) -- A second batch of the Sinovac COVID-19 vaccine that Cambodia purchased from China arrived in Phnom Penh,...
Xinhua · 2d ago
Sinovac vaccine 67% effective against symptomatic infection in real-world study - Reuters
Sinovac Biotech's (SVA) CoronaVac COVID-19 vaccine was 67% effective in preventing symptomatic infection, according to real-world data from Chile, Reuters reports.A report from the Chilean health ministry found that the
Seekingalpha · 3d ago
UPDATE 4-Game changer: Chile hails Sinovac's 67% effectiveness in study
reuters.com · 3d ago
UPDATE 2-China's Sinovac vaccine 67% effective against symptomatic infection -Chile report
reuters.com · 3d ago
China's Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection - Chile govt report
reuters.com · 3d ago
Market Chatter: Sinovac Biotech's COVID-19 Vaccine 67% Effective in Chilean Study
MT Newswires · 3d ago
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SVA. Analyze the recent business situations of Sinovac Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.27%
Pharmaceuticals & Medical Research
-0.37%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Weidong Yin
Chairman/Chief Executive Officer/President/Secretary/Director
WeiDong Yin
Chief Financial Officer/Vice President
Nan Wang
Vice President/Director of Sales/Director of Marketing
Xiaomei Yin
Director
Jianzeng Cao
Vice President
Qiang Gao
Director
Fung Qiu Hoi
Vice President
Jing Li
Independent Director
Simon Anderson
Director
Pengfei Li
Director
Guowei Wang
Independent Director
Shan Fu
Independent Director
Jue Lee
Independent Director
Kenneth Lee
Independent Director
Yuk Lam Lo
Independent Director
Meng Mei
No Data
About SVA
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Webull offers kinds of Sinovac Biotech Ltd. stock information, including NASDAQ:SVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SVA stock methods without spending real money on the virtual paper trading platform.